Your browser doesn't support javascript.
loading
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
Sandkovsky, Uriel; Podany, Anthony T; Fletcher, Courtney V; Owen, Andrew; Felton-Coleman, Angela; Winchester, Lee C; Robertson, Kevin; Swindells, Susan.
Afiliação
  • Sandkovsky U; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA usandkovsky@unmc.edu.
  • Podany AT; Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
  • Fletcher CV; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
  • Owen A; Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
  • Felton-Coleman A; Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Winchester LC; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
  • Robertson K; Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
  • Swindells S; Department of Neurology, University of North Carolina, Chapel Hill, NC, USA.
J Antimicrob Chemother ; 72(1): 200-204, 2017 01.
Article em En | MEDLINE | ID: mdl-27655857
BACKGROUND: Pharmacokinetics (PK) and pharmacodynamics of efavirenz and its 8-hydroxy metabolite (8-OH-efavirenz) have not been robustly evaluated in older HIV-infected persons. OBJECTIVES: We investigated relationships between neuropsychological (NP) performance and efavirenz and 8-OH-efavirenz PK in HIV-infected individuals >50 years of age. METHODS: A cross-sectional study of HIV-infected adults on an efavirenz-containing regimen. The 12 and 18 h post-dose plasma efavirenz and 8-OH-efavirenz were quantified. CYP2B6 polymorphisms were investigated. Participants underwent neuropsychological tests; surveys were used for depression, sleep quality and anxiety. We investigated potential correlations of efavirenz and 8-OH-efavirenz plasma concentrations with NP performance, sleep, depression, anxiety and CYP2B6 polymorphisms. RESULTS: Thirty participants (24 men and 6 women) with mean age 57 years (range 50-68). Plasma efavirenz concentrations did not correlate with NP performance; however, higher plasma 8-OH-efavirenz correlated with better learning (P = 0.002), language (P = 0.002) and total NP z-scores (P = 0.003). No correlation was seen for efavirenz or 8-OH-efavirenz with sleep, anxiety or depression. Median 12 and 18 h efavirenz plasma concentrations were 1967 ng/mL (IQR 1476-2394) and 1676 ng/mL (IQR 1120-2062), respectively. Median 12 and 18 h 8-OH-efavirenz plasma concentrations were 378 ng/mL (IQR 223-589) and 384 ng/mL (IQR 216-621), respectively. CYP2B6 G516T was associated with significantly higher plasma efavirenz at 12 and 18 h (P = 0.02) but not worse NP function. CONCLUSIONS: Better neurocognitive functioning was associated with higher 8-OH-efavirenz but not efavirenz plasma concentrations. No correlation was observed with sleep or depression. These findings point to a need for greater understanding of the metabolic profile of efavirenz and 8-OH-efavirenz in plasma and the CNS and relationships with antiviral effect and neurotoxicity.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Complexo AIDS Demência / Inibidores da Transcriptase Reversa / Benzoxazinas Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Complexo AIDS Demência / Inibidores da Transcriptase Reversa / Benzoxazinas Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos